Thank you for Subscribing to CIO Applications Weekly Brief

Data Science to Expedite Drug Discovery with Artificial Intelligence and Machine Learning, Says Frost & Sullivan
Frost & Sullivan's recent analysis, ‘Data Science Impacting the Pharmaceutical Industry’, discovered that data science tools are promising technologies transforming drug discovery speed, costs, and efficiency.
By
CIO Applications | Monday, February 26, 2024

Data Science Impacting the Pharmaceutical Industry is the latest addition to Frost & Sullivan's Technical Insights research and analyses available via the Frost & Sullivan Leadership Council, which helps organizations figure out a continuous flow of growth opportunities to succeed in an unpredictable future.
FREMONT, CA: Frost & Sullivan's recent analysis, ‘Data Science Impacting the Pharmaceutical Industry’, discovered that data science tools are promising technologies transforming drug discovery speed, costs, and efficiency. When combined with other emerging tech areas, artificial intelligence (AI) technologies move to the next phase of progress. Therefore, they are expected to witness adoption by biotech and pharma companies in the next four to five years. Further, with the COVID-19 pandemic, AI and machine learning (ML) can be utilized for clinical trials and drug research against the coronavirus to screen large databases and perform docking studies to identify existing potential drugs or design new drugs using advanced learning algorithms.
"Applying data science tools in healthcare, especially for drug discovery, has a huge potential to systematically change the entire existing practices and methods," remarked Aarthi Janakiraman, Technical Insights Research Manager at Frost & Sullivan. "Additionally, pharmaceutical companies and hospitals are adopting this system rapidly, and its application is going to be established in all branches of healthcare."
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Janakiraman stated, "Integrating AI and ML methods into drug discovery pipelines would cut down cost and time, and increase the efficiency of the entire research and development (R&D) process. Going forward, big pharma and mid-sized biotech companies can benefit by partnering with core AI startups and reducing the costs involved in setting up their own capabilities."
Data Science Impacting the Pharmaceutical Industry is the latest addition to Frost & Sullivan's Technical Insights research and analyses available via the Frost & Sullivan Leadership Council, which helps organizations figure out a continuous flow of growth opportunities to succeed in an unpredictable future.
More in News

